Skip to main content
SpringerLink
Log in
Book cover

Prostate Cancer pp 1–19Cite as

Prostate Cancer Screening in African-American Men

  • Chapter
  • First Online:

  • 1116 Accesses

Abstract

African-American men exhibit higher-risk prostate cancer and exhibit worse outcomes when compared to other racial and ethnic groups. There remain important knowledge gaps specifically surrounding the implications of this observed outcome disparity with respect to appropriateness and intensity of active surveillance in African-American men. Only approximately a tenth of the men in most active surveillance programs are African-American, yet the results are generalized as applying to all men equally. Nevertheless, because even “very low-risk” prostate cancer appears different pathologically and epidemiologically, African-American men must understand these risks when they elect management for prostate cancer. Most specifically, they must be aware that if they decide on active surveillance, aggressive cancer may be missed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M. Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER Cancer Statistics Review, 1975–2011. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.

  2. Odedina FT, et al. Prostate cancer disparities in black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer. 2009;4:S2.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Sundi D, et al. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol. 2013;31:2991–7.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Resnick MJ, Canter DJ, Guzzo TJ, et al. Does race affect postoperative outcomes in patients with low-risk prostate cancer who undergo radical prostatectomy? Urology. 2009;73:620–3.

    Article  CAS  PubMed  Google Scholar 

  5. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol. 2010;183:1792–6.

    Article  PubMed  Google Scholar 

  6. Mahal BA, et al. Getting back to equal: the influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol. 2014;32:1285–91.

    Article  PubMed  Google Scholar 

  7. Taksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer. 2012;118:4280–9.

    Article  PubMed  Google Scholar 

  8. Cowen ME, Kattan MW, Miles BJ. A national survey of attitudes regarding participation in prostate carcinoma testing. Cancer. 1996;78:1952–7.

    Article  CAS  PubMed  Google Scholar 

  9. Evans S, et al. Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: the PROCESS cohort study. Br J Cancer. 2010;102:249–54.

    Article  CAS  PubMed  Google Scholar 

  10. Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK. Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol Biomark Prev. 2014;23:1505–11.

    Article  Google Scholar 

  11. Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, Hugosson J. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Service Task Force review. J Clin Oncol. 2012;30:2581–4.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Preventive Services Task Force US. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–34.

    Article  Google Scholar 

  13. Fleshner K, Carlsson SV, Roobol MJ. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol. 2017;14:26–37.

    Article  CAS  PubMed  Google Scholar 

  14. Lee DJ, MAllin K, Graves A, Chang SS, et al. Recent changes in prostate cancer screening practices and epidemiology. J Urol. 2017;198(6):1230–40.

    Article  PubMed  Google Scholar 

  15. Buzzoni C, et al. Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European randomized study of screening for prostate cancer. Eur Urol. 2015;68:885–90.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Schroder FH, et al. The European randomized study of screening for prostate cancer—prostate cancer mortality at 13 years of follow-up. Lancet. 2014;382:2027–35.

    Article  Google Scholar 

  17. Murphy DG, Loeb S. Prostate cancer: growth of AS in the USA signals reduction in overtreatment. Nat Rev Urol. 2015;12:604–5.

    Article  PubMed  Google Scholar 

  18. Bibbins-Domingo K, Grossman DC, Curry SJ. The US Preventive Service Task Force 2017 draft recommendation statement on screening for prostate cancer: an invitation to review and comment. JAMA. 2017;317:1949–50.

    Article  PubMed  Google Scholar 

  19. Shenoy D, et al. Do African-American men need separate prostate cancer screening guidelines? BMC Urol. 2016;16:19.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Tangen CM, et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894, & S9346). J Urol. 2012;188:1164–9.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Sarma AV, et al. Racial differences in longitudinal changes in serum prostate-specific antigen levels: the Olmsted County Study and the Flint Men’s Health Study. J Urol. 2014;83:88–93.

    Article  Google Scholar 

  22. McGreevy K, Rodgers K, Lipsitz S, Bissada N, Hoel D. Impact of race and baseline PSA on longitudinal PSA. Int J Cancer. 2006;118:1773–6.

    Article  CAS  PubMed  Google Scholar 

  23. Henderson RJ, Eastham JA, Culkin DJ, Kattan MW, Whatley T, Mata J, Venable D, Sartor O. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst. 1997;89:134–8.

    Article  CAS  PubMed  Google Scholar 

  24. Moul JW, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995;274:1277–81.

    Article  CAS  PubMed  Google Scholar 

  25. Mavropoulos JC, et al. Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? Urology. 2007;69:1138–42.

    Article  PubMed  Google Scholar 

  26. Zhang W, Sesterhenn IA, Connelly RR, Mostofi FK, Moul JW. Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. J Urol. 2000;163:131–6.

    Article  CAS  PubMed  Google Scholar 

  27. Kubricht WS 3rd, Williams BJ, Whatley T, Pinckard P, Eastham JA. Serum testosterone levels in African-American and white men undergoing prostate biopsy. Urology. 1999;54:1035–8.

    Article  PubMed  Google Scholar 

  28. Bensen JT, et al. Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans. Prostate. 2013;73:11–22.

    Article  CAS  PubMed  Google Scholar 

  29. Campbell MF, Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh urology, Epidemiology, etiology, and prevention of prostate cancer. 11th ed. Philadelphia, PA: WB Saunders; 2016. p. 2546.

    Google Scholar 

  30. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994;81:1600–8.

    Article  Google Scholar 

  31. Lange EM. Male reproductive cancers: epidemiology, pathology, and genetics. In: Foulkes WD, Cooney KA, editors. . New York: Springer; 2010. p. 203–28.

    Chapter  Google Scholar 

  32. Lichtenstein P, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.

    Article  CAS  PubMed  Google Scholar 

  33. Lin DW, et al. Genetics variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomark Prev. 2011;20:1928–36.

    Article  CAS  Google Scholar 

  34. Cooney KA, et al. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst. 1997;89:955–9.

    Article  CAS  PubMed  Google Scholar 

  35. Ewing CM, et al. Germline mutations in HOVB13 and prostate-cancer risk. N Engl J Med. 2012;366:141–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Witte JS, et al. HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease. Cancer Epidemiol Biomark Prev. 2013;22:675–80.

    Article  CAS  Google Scholar 

  37. Eeles R, et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol. 2014;11:18–31.

    Article  CAS  PubMed  Google Scholar 

  38. Castro E, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31:1748–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Cooney KA. Inherited predisposition to prostate cancer: from gene discovery to clinical impact. Trans Am Clin Climatol Assoc. 2017;128:14–23.

    PubMed  PubMed Central  Google Scholar 

  40. Zheng SL, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358:910.

    Article  CAS  PubMed  Google Scholar 

  41. Powell IJ, et al. Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomark Prev. 2013;22:891–7.

    Article  CAS  Google Scholar 

  42. Yamoah K, et al. Novel biomarker signature that may predict aggressive disease in African-American men with prostate cancer. J Clin Oncol. 2015;33:2789–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Tomlins SA, et al. Characterization of 1577 primary prostate cancers reveals novel biological and clinic opathologic insights into molecular subtypes. Eur Urol. 2015;68:555–67.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Haiman CA, et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet. 2011;43:570–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Freedman ML, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A. 2006;103:14068–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Faisal FA, et al. Racial variations in prostate cancer molecular subtypes and androgen receptor signaling reflect anatomic tumor location. Eur Urol. 2016;70:14–7.

    Article  CAS  PubMed  Google Scholar 

  47. Sundi D, et al. Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men. J Urol. 2014;191:60–7.

    Article  PubMed  Google Scholar 

  48. Tiguert R, Kabbani W, Sakr W, Gheiler EL, Pontes JE. Origin and racial distribution of glandular tissue in the anterior compartment of the prostate: an autopsy study. Prostate. 1999;39:310–5.

    Article  CAS  PubMed  Google Scholar 

  49. Pettaway CA, et al. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol. 1998;160:437–42.

    Article  CAS  PubMed  Google Scholar 

  50. Beilin J, Ball EM, Favaloro JM, Zajac JD. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol. 2000;25:85–96.

    Article  CAS  PubMed  Google Scholar 

  51. Giovannucci E, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A. 1997;94:3320–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Bennett CL, et al. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol. 2002;20:3599–604.

    Article  CAS  PubMed  Google Scholar 

  53. Price DK, et al. Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. J Urol. 2010;184:2297–302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Gilligan T, et al. Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin Prostate Cancer. 2004;3:98–103.

    Article  CAS  PubMed  Google Scholar 

  55. Freedman ML, et al. Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am J Hum Genet. 2005;76:82–90.

    Article  CAS  PubMed  Google Scholar 

  56. Gaston KE, et al. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol. 2003;170:990–3.

    Article  CAS  PubMed  Google Scholar 

  57. de la Calle C, Patil D, Wei JT, et al. Multicenter evaluation of the prostate health index to detect aggressive prostate cancer in biopsy naive men. J Urol. 2015;194:65–72.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Loeb S, Sanda MG, Broyles DL, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol. 2015;193:1163–9.

    Article  PubMed  Google Scholar 

  59. Schwen ZR, Tosioan JJ, Sokoll LJ, et al. Prostate health index (PHI) predicts high-stage pathology in African American men. J Urol. 2016;90:136–40.

    Article  Google Scholar 

  60. Vickers AJ, Gupta A, Savage CJ, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomark Prev. 2011;20:255–61.

    Article  CAS  Google Scholar 

  61. Nordstrom T, Vickers A, Assel M, Lilja H, Gronberg H, Eklund M. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol. 2015;68:139–44.

    Article  PubMed  CAS  Google Scholar 

  62. Russo GI, Regis F, Castelli T, et al. A systematic review and meta-analysis of the diagnostic accuracy of prostate health index and 4-Kallikrein panel score in predicting overall and high-grade prostate cancer. Clin genitour. Cancer. 2016;15:429–39.

    Google Scholar 

  63. Van Neste L, Hendriks RJ, Dijkstra S, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol. 2016;70:740–8.

    Article  PubMed  CAS  Google Scholar 

  64. O’Malley PG, et al. Racial variation in the utility of urinary biomarkers PCA3 and T2ERG in a large multicenter study. J Urol. 2017;198:42–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  65. Schoots IG, Roobol MJ, Nieboer D, et al. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol. 2015;68:438–50.

    Article  PubMed  Google Scholar 

  66. Shin T, et al. Detection of prostate cancer using magnetic resonance imaging/ultrasonography image-fusion targeted biopsy in African-American men. BJU Int. 2017;120:233–8.

    Article  CAS  PubMed  Google Scholar 

  67. El-Shater Bosaily A, Parker C, Borwn LC, et al. PROMIS: prostate MR imaging study: a paired validating cohort study evaluating the role of multi-parametirc MRI in men with clinical suspicion of prostate cancer. Contemp Clin Trials. 2015;42:26–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Grenabo Bergdahl A, Wilderang U, Aus G, et al. Role of magnetic resonance imaging in prostate cancer screening: a pilot study within the Goteborg Randomised Screening Trial. Eur Urol. 2016;70:566–73.

    Article  PubMed  Google Scholar 

  69. Kongnyuy M, et al. The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men. Urol Oncol. 2016;34:254.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Smith ZL, Eggener SE, Murphy AB. African-American prostate cancer disparities. Curr Urol Reports. 2017;18:81.

    Article  Google Scholar 

  71. Carroll, PR, Parsons JK, Andriole, G, et al. NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2017. www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

  72. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA. 2003;289:2695–700.

    Article  CAS  PubMed  Google Scholar 

  73. Nordstrom T, Adolfsson J, Gronberg H, Eklund M. Repeat prostate-specific antigen tests before prostate biopsy decisions. J Natl Cancer Inst. 2016;108(12):djw165.

    Article  PubMed  CAS  Google Scholar 

  74. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. N Engl J Med. 2004;350:2239–46.

    Article  CAS  PubMed  Google Scholar 

  75. Loeb S, Roehl KA, Antenor JV, et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years. Urology. 2006;67:316–20.

    Article  PubMed  Google Scholar 

  76. Kryvenko ON, Balise R, Soodana Prakash N, Epstein JI. African-American men with Gleason score 3+3=6 prostate cancer produce less prostate specific antigen than Caucasian men: a potential impact on active surveillance. J Urol. 2016;195:301–6.

    Article  PubMed  Google Scholar 

  77. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst. 2006;98:529–34.

    Article  PubMed  Google Scholar 

  78. Kaplan DJ, Boorjian SA, Ruth K, et al. Evaluation of the prostate cancer prevention trial risk calculator in a high-risk screening population. BJU Int. 2010;105:334–7.

    Article  PubMed  Google Scholar 

  79. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate Cancer Trends 1973–1995. SEER Program. National Institutes of Health Publication 99-4543. Bethesda, MD: National Cancer Institute; 1999.

    Google Scholar 

  80. Merrill RM, Brawley OW. Prostate cancer incidence and mortality rates among whites and black men. Epidemiology. 1997;8:126–31.

    Article  CAS  PubMed  Google Scholar 

  81. Jepson C, Kessler LG, Portnoy B, Gibbs T. Black- white differences in cancer prevention knowledge and behavior. Am J Public Health. 1991;81:501–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. National Center for Chronic Disease Prevention and Health Promotion. Chronic disease in minority populations. Atlanta, GA: Centers for Disease Control and Prevention; 1992.

    Google Scholar 

  83. Freeman VL, Durazo-Arvizu R, Keys L, et al. Racial differences in survival among men with prostate cancer and comorbidity at time of diagnosis. Am J Public Health. 2004;94(5):803–8.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Cohen JH, Schoenbach VJ, Kaufman JS, et al. Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States). Cancer Causes Control. 2006;17(6):803–11.

    Article  PubMed  Google Scholar 

  85. Mahal BA, Aizer AA, Ziehr DR, et al. Trends in disparate treatment of African-American men with localize prostate cancer across National Comprehensive Cancer Network risk groups. Urology. 2014;84(2):386–92.

    Article  PubMed  Google Scholar 

  86. Zeliadt SB, Potosky AL, Etzioni R, et al. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004;64(6):1171–6.

    Article  PubMed  Google Scholar 

  87. Mahal BA, Ziehr DR, Aizer AA, et al. Getting back to equal: the influence of insurance status of racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol. 2014;32(8):1895–1.

    Article  Google Scholar 

  88. Daskivich TJ, Kwan L, Dash A, Litwin MS. Racial parity in tumor burden, treatment choice and survival outcomes in men with prostate cancer in the VA healthcare system. Prostate Cancer Prostatic Dis. 2015;18:104–9.

    Article  CAS  PubMed  Google Scholar 

  89. Cullen J, Kuo H-C, Chen Y, et al. Prostate cancer outcomes for African American and Caucasian patients undergoing radical prostatectomy. JCO. 2017;35(6_suppl):40.

    Article  Google Scholar 

  90. Yamoah K, Walker A, Spangler E, et al. African-American race is a predictor of seminal vesicle invasion following radical prostatectomy. Clin Genitourin Cancer. 2015;13(2):e65–72.

    Article  PubMed  Google Scholar 

  91. Faisal FA, Sundi D, Cooper JL, et al. Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up. Urology. 2014;84(6):1434–41.

    Article  PubMed  Google Scholar 

  92. Gökce MI, Sundi D, Schaeffer E, Pettaway C. Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review. Prostate Cancer Prostatic Dis. 2017;20(2):127–36.

    Article  PubMed  Google Scholar 

  93. Tyson MD, Alvarez J, Koyama T, et al. Racial variation in patient-reported outcomes following treatment for localized prostate cancer: results from the CEASAR study. Eur Urol. 2017;72(2):307–14.

    Article  PubMed  Google Scholar 

  94. Sanchez-Ortiz RF, Troncoso P, Babaian RJ, et al. African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer. 2006;107(1):75–82.

    Article  PubMed  Google Scholar 

  95. Barocas DA, Gray DT, Fowke JH. Racial variation in the quality of surgical care for prostate cancer. J Urol. 2012;188(4):1279–85.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Klabunde CN, Potosky AL, Harlan LC, Kramer BS. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998;36:1337–48.

    Article  CAS  PubMed  Google Scholar 

  97. Nambudiri VE, Landrum MB, McNeil BJ, et al. Understanding variation in primary prostate cancer treatment within the Veterans Health Administration. Urology. 2012;79:537–45.

    Article  PubMed  Google Scholar 

  98. Turner W. The index of the pelvic brim as a basis of classification. J Anat Physiol. 1885;20:125–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Swords K, Wallen EM, Pruthi RS. The impact of race on prostate cancer detection and choice of treatment in men undergoing a contemporary extended biopsy approach. Urol Oncol. 2010;28:280–4.

    Article  PubMed  Google Scholar 

  101. Ziehr DR, Mahal BA, Aizer AA, et al. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol. 2015;33:18.e7–18.e13.

    Article  Google Scholar 

  102. Yamoah K, Beecham K, Hegarty SE, et al. Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes. BMC Cancer. 2013;13:23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Winkfield KM, Chen MH, Dosoretz DE, et al. Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2011;81(4):e345–50.

    Article  PubMed  Google Scholar 

  104. Lowrance WT, Elkin ED, Yee DS, et al. Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int. 2012;109:1309–14.

    Article  PubMed  Google Scholar 

  105. Lu-Yao G, Moore DF, Oleynick J, et al. Use of hormonal therapy in men with metastatic prostate cancer. J Urol. 2006;176:526–31.

    Article  PubMed  Google Scholar 

  106. Bergman J, Saigal CS, Lorenz KA, et al. Hospice use and high-intensity care in men dying of prostate cancer. Arch Intern Med. 2011;171(3):204–10.

    Article  PubMed  Google Scholar 

  107. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care ofr patients with metastatic non-small-cell lung cancer. NEJM. 2010;363(8):733–42.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA

    Aaron A. Laviana M.D., Peter A. Reisz & Matthew J. Resnick M.D.

  2. Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN, USA

    Matthew J. Resnick M.D.

  3. Tennessee Valley VA Health Care System, Nashville, TN, USA

    Matthew J. Resnick M.D.

Authors
  1. Aaron A. Laviana M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter A. Reisz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew J. Resnick M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aaron A. Laviana M.D. .

Editor information

Editors and Affiliations

  1. Department of Urologic Surgery and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

    Sam S. Chang

  2. Department of Urology, University of Oklahoma Medical Center, Oklahoma City, Oklahoma, USA

    Michael S. Cookson

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Laviana, A.A., Reisz, P.A., Resnick, M.J. (2018). Prostate Cancer Screening in African-American Men. In: Chang, S., Cookson, M. (eds) Prostate Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-78646-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-78646-9_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-78645-2

  • Online ISBN: 978-3-319-78646-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation